CL2014000181A1 - Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11). - Google Patents

Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11).

Info

Publication number: CL2014000181A1
Authority: CL; Chile
Prior art keywords: antibody; divisional; met; vector; nucleic acid
Prior art date: 2008-12-02

Application number

CL2014000181A

Other languages

English (en)

Inventor

Liliane Goetsh

Thierry Wurch

Cedric Bes

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-02

Filing date

2014-01-24

Publication date

2014-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000181(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-02 Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en

2014-01-24 Application filed by Pf Medicament filed Critical Pf Medicament

2014-07-25 Publication of CL2014000181A1 publication Critical patent/CL2014000181A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)

CL2014000181A 2008-12-02 2014-01-24 Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11). CL2014000181A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/IB2008/055663 WO2010064089A1 (en)	2008-12-02	2008-12-02	Novel anti-cmet antibody
US18450209P	2009-06-05	2009-06-05

Publications (1)

Publication Number	Publication Date
CL2014000181A1 true CL2014000181A1 (es)	2014-07-25

Family

ID=41693124

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2011001296A CL2011001296A1 (es)	2008-12-02	2011-06-01	Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales.
CL2014000181A CL2014000181A1 (es)	2008-12-02	2014-01-24	Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11).

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL2011001296A CL2011001296A1 (es)	2008-12-02	2011-06-01	Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales.

Country Status (38)

Country	Link
US (4)	US8741290B2 (es)
EP (4)	EP3135691B1 (es)
JP (3)	JP5863458B2 (es)
KR (1)	KR101838299B1 (es)
CN (2)	CN102227446B (es)
AR (1)	AR074439A1 (es)
AU (3)	AU2009328318C1 (es)
BR (2)	BRPI0923231B8 (es)
CA (1)	CA2743433C (es)
CL (2)	CL2011001296A1 (es)
CO (1)	CO6382139A2 (es)
CR (1)	CR20110324A (es)
CY (2)	CY1119172T1 (es)
DK (2)	DK3135691T3 (es)
EC (1)	ECSP11011127A (es)
ES (3)	ES2629855T3 (es)
GE (2)	GEP20146207B (es)
HR (2)	HRP20171011T8 (es)
HU (3)	HUE051288T2 (es)
IL (2)	IL213273A0 (es)
LT (2)	LT3135691T (es)
MA (1)	MA32892B1 (es)
MX (2)	MX2011005677A (es)
MY (2)	MY185200A (es)
NZ (1)	NZ593853A (es)
PE (1)	PE20120343A1 (es)
PH (1)	PH12015501515A1 (es)
PL (3)	PL3431502T3 (es)
PT (3)	PT2370468T (es)
RS (2)	RS58018B1 (es)
RU (2)	RU2560257C2 (es)
SA (2)	SA109300720B1 (es)
SG (2)	SG187518A1 (es)
SI (3)	SI3135691T1 (es)
TN (1)	TN2011000216A1 (es)
TW (2)	TWI523866B (es)
WO (1)	WO2010069765A1 (es)
ZA (1)	ZA201105164B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2014681A1 (en)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) *	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
EP2287197A1 (en) *	2009-08-21	2011-02-23	Pierre Fabre Medicament	Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US9068011B2 (en)	2010-03-10	2015-06-30	Genmab A+S	Monoclonal antibodies against c-Met
AU2011296085A1 (en)	2010-09-03	2013-03-28	Academia Sinica	Anti-c-Met antibody and methods of use thereof
WO2012059562A1 (en)	2010-11-03	2012-05-10	Argen-X-Bv	C-met antibody combinations
EP2710042A2 (en)	2011-05-16	2014-03-26	Fabion Pharmaceuticals, Inc.	Multi-specific fab fusion proteins and methods of use
KR101865223B1 (ko)	2011-10-05	2018-06-08	삼성전자주식회사	항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) *	2011-10-05	2013-04-15	삼성전자주식회사	ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013064700A2 (en)	2011-11-03	2013-05-10	Argen-X B.V.	Chimeric polypeptides and methods of use
KR101463098B1 (ko)	2011-11-28	2014-11-27	한국생명공학연구원	ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
KR101910601B1 (ko)	2011-12-22	2018-10-23	삼성전자주식회사	면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
CA2877573A1 (en) *	2012-06-21	2013-12-27	Sorrento Therapeutics, Inc.	Antigen binding proteins that bind c-met
US9931400B2 (en)	2012-09-12	2018-04-03	Samsung Electronics Co., Ltd.	Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
ES2530968T3 (es)	2012-10-12	2015-03-09	Spirogen Sarl	Pirrolobenzodiazepinas y conjugados de las mismas
WO2014140174A1 (en)	2013-03-13	2014-09-18	Spirogen Sàrl	Pyrrolobenzodiazepines and conjugates thereof
KR102049990B1 (ko) *	2013-03-28	2019-12-03	삼성전자주식회사	c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9994644B2 (en)	2013-04-30	2018-06-12	Agency For Science, Technology And Research	mAB 2 anti-Met antibody
US9567641B2 (en) *	2013-07-03	2017-02-14	Samsung Electronics Co., Ltd.	Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en)	2013-11-15	2017-08-01	Samsung Electronics Co., Ltd.	Method of combination therapy using an anti-C-Met antibody
RU2656153C1 (ru) *	2013-12-20	2018-05-31	Девелопмент Сентер Фор Байотекнолоджи	Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
JP6531166B2 (ja)	2014-09-10	2019-06-12	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びそのコンジュゲート
EP3270918A4 (en) *	2015-03-16	2018-10-24	Celldex Therapeutics, Inc.	Anti-met antibodies and methods of use thereof
ES2896709T3 (es) *	2016-02-05	2022-02-25	Helixmith Co Ltd	Anticuerpos anti-c-Met y usos de los mismos
CA3017776A1 (en)	2016-03-15	2017-09-21	Generon (Shanghai) Corporation Ltd.	Multispecific fab fusion proteins and use thereof
NZ748314A (en) *	2016-05-17	2023-07-28	Abbvie Inc	Anti-cmet antibody drug conjugates and methods for their use
US10457726B2 (en)	2016-06-30	2019-10-29	University Of Connecticut	Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
WO2018069289A1 (en)	2016-10-11	2018-04-19	Medimmune Limited	Antibody-drug conjugates with immune-mediated therapy agents
RU2741228C2 (ru) *	2016-11-14	2021-01-22	Общество С Ограниченной Ответственностью "Панацела Лабс"	Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
TWI782930B (zh)	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (en) *	2017-01-04	2018-07-12	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh)	2017-11-13	2022-09-20	同济大学苏州研究院	c-MET激动型抗体及其用途
GB201803892D0 (en) *	2018-03-12	2018-04-25	Ultrahuman Six Ltd	C-met binding agents
CN113286616A (zh)	2018-05-23	2021-08-20	Adc治疗有限公司	分子佐剂
AU2019318087B2 (en) *	2018-08-08	2025-09-18	Dragonfly Therapeutics, Inc.	Proteins binding NKG2D, CD 16 and a tumor-associated antigen
EP3847196A4 (en)	2018-09-07	2023-01-04	ITabMed (HK) Limited	BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109541221B (zh) *	2018-10-24	2022-03-22	益善生物技术股份有限公司	一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) *	2018-11-14	2022-01-20	주식회사 헬릭스미스	안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020198731A2 (en) *	2019-03-28	2020-10-01	Danisco Us Inc	Engineered antibodies
MX2022002886A (es)	2019-09-16	2022-04-06	Regeneron Pharma	Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
KR20230018454A (ko)	2020-09-01	2023-02-07	레메젠 코, 리미티드	항-c-Met 항체-약물 접합체 및 이의 용도
WO2022079211A1 (en)	2020-10-16	2022-04-21	Adc Therapeutics Sa	Glycoconjugates
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
WO2022216796A1 (en)	2021-04-06	2022-10-13	Abbvie Biotherapeutics Inc.	Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
US20240376214A1 (en) *	2021-04-08	2024-11-14	Byondis B.V.	Anti-c-met antibodies and antibody-drug conjugates
AR125473A1 (es)	2021-04-29	2023-07-19	Abbvie Inc	Conjugados de anticuerpo anti-c-met y fármaco
EP4426727A2 (en)	2021-11-03	2024-09-11	Hangzhou Dac Biotech Co., Ltd.	Specific conjugation of an antibody
US20230285394A1 (en)	2022-03-11	2023-09-14	Abbvie Biotherapeutics Inc.	Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
WO2024243450A1 (en)	2023-05-23	2024-11-28	Abbvie Inc.	Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4424200A (en)	1979-05-14	1984-01-03	Nuc Med Inc.	Method for radiolabeling proteins with technetium-99m
US4479930A (en)	1982-07-26	1984-10-30	Trustees Of The University Of Massachusetts	Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en)	1989-11-01	1989-12-20	Pa Consulting Services	Bleaching of hair
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
WO1994004679A1 (en) *	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5639641A (en) *	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5686292A (en) *	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2002055106A2 (en) *	2001-01-09	2002-07-18	Merck Patent Gmbh	Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2004072117A2 (en) *	2003-02-13	2004-08-26	Pharmacia Corporation	Antibodies to c-met for the treatment of cancers
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
US20050233960A1 (en)	2003-12-11	2005-10-20	Genentech, Inc.	Methods and compositions for inhibiting c-met dimerization and activation
PT1773885E (pt) *	2004-08-05	2010-07-21	Genentech Inc	Antagonistas anti-cmet humanizados
US8008443B2 (en) *	2005-04-26	2011-08-30	Medimmune, Llc	Modulation of antibody effector function by hinge domain engineering
KR20130023356A (ko) *	2005-07-18	2013-03-07	메다렉스, 인코포레이티드	인간 항-ｂ7ｒｐ1 중화 항체
EP1913027B1 (en) *	2005-07-28	2015-03-04	Novartis AG	M-csf specific monoclonal antibody and uses thereof
JP5536445B2 (ja) *	2006-03-30	2014-07-02	ノバルティスアーゲー	ｃ−Ｍｅｔの抗体の組成物およびその使用方法
EP2014681A1 (en) *	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en)	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody

2009
- 2009-12-01 AR ARP090104624A patent/AR074439A1/es active IP Right Grant
- 2009-12-02 AU AU2009328318A patent/AU2009328318C1/en active Active
- 2009-12-02 RS RS20181344A patent/RS58018B1/sr unknown
- 2009-12-02 RS RS20170671A patent/RS56204B1/sr unknown
- 2009-12-02 LT LTEP16192250.5T patent/LT3135691T/lt unknown
- 2009-12-02 PT PT97713242T patent/PT2370468T/pt unknown
- 2009-12-02 HU HUE18188726A patent/HUE051288T2/hu unknown
- 2009-12-02 DK DK16192250.5T patent/DK3135691T3/en active
- 2009-12-02 CA CA2743433A patent/CA2743433C/en active Active
- 2009-12-02 RU RU2011124751/10A patent/RU2560257C2/ru active
- 2009-12-02 CN CN200980148150.4A patent/CN102227446B/zh active Active
- 2009-12-02 CN CN201310286587.2A patent/CN103351438B/zh active Active
- 2009-12-02 ES ES09771324.2T patent/ES2629855T3/es active Active
- 2009-12-02 LT LTEP09771324.2T patent/LT2370468T/lt unknown
- 2009-12-02 SG SG2013005772A patent/SG187518A1/en unknown
- 2009-12-02 GE GEAP200912919A patent/GEP20146207B/en unknown
- 2009-12-02 GE GEAP200912279A patent/GEP20135930B/en unknown
- 2009-12-02 HU HUE16192250A patent/HUE040553T2/hu unknown
- 2009-12-02 PL PL18188726T patent/PL3431502T3/pl unknown
- 2009-12-02 KR KR1020117013758A patent/KR101838299B1/ko active Active
- 2009-12-02 HR HRP20171011TT patent/HRP20171011T8/hr unknown
- 2009-12-02 WO PCT/EP2009/066201 patent/WO2010069765A1/en not_active Ceased
- 2009-12-02 PT PT16192250T patent/PT3135691T/pt unknown
- 2009-12-02 SI SI200931893T patent/SI3135691T1/sl unknown
- 2009-12-02 TW TW103130374A patent/TWI523866B/zh active
- 2009-12-02 DK DK09771324.2T patent/DK2370468T3/en active
- 2009-12-02 MX MX2011005677A patent/MX2011005677A/es active IP Right Grant
- 2009-12-02 SG SG2011038817A patent/SG171851A1/en unknown
- 2009-12-02 BR BRPI0923231A patent/BRPI0923231B8/pt active IP Right Grant
- 2009-12-02 US US13/132,211 patent/US8741290B2/en active Active
- 2009-12-02 RU RU2015127471A patent/RU2015127471A/ru not_active Application Discontinuation
- 2009-12-02 PL PL09771324T patent/PL2370468T3/pl unknown
- 2009-12-02 NZ NZ593853A patent/NZ593853A/xx unknown
- 2009-12-02 EP EP16192250.5A patent/EP3135691B1/en active Active
- 2009-12-02 TW TW098141151A patent/TWI459964B/zh active
- 2009-12-02 SI SI200931680T patent/SI2370468T1/sl unknown
- 2009-12-02 HU HUE09771324A patent/HUE035047T2/en unknown
- 2009-12-02 MY MYPI2011002426A patent/MY185200A/en unknown
- 2009-12-02 PL PL16192250T patent/PL3135691T3/pl unknown
- 2009-12-02 MY MYPI2020006937A patent/MY192567A/en unknown
- 2009-12-02 ES ES16192250T patent/ES2697098T3/es active Active
- 2009-12-02 PT PT181887266T patent/PT3431502T/pt unknown
- 2009-12-02 EP EP20187010.2A patent/EP3757132A1/en active Pending
- 2009-12-02 EP EP09771324.2A patent/EP2370468B1/en active Active
- 2009-12-02 SI SI200932092T patent/SI3431502T1/sl unknown
- 2009-12-02 JP JP2011539008A patent/JP5863458B2/ja active Active
- 2009-12-02 ES ES18188726T patent/ES2827277T3/es active Active
- 2009-12-02 BR BR122019023930-4A patent/BR122019023930B1/pt active IP Right Grant
- 2009-12-02 EP EP18188726.6A patent/EP3431502B1/en active Active
- 2009-12-02 PE PE2011001117A patent/PE20120343A1/es active IP Right Grant
- 2009-12-05 SA SA109300720A patent/SA109300720B1/ar unknown
- 2009-12-05 SA SA112331005A patent/SA112331005B1/ar unknown
2011
- 2011-05-03 TN TN2011000216A patent/TN2011000216A1/fr unknown
- 2011-05-30 MX MX2015000383A patent/MX341014B/es unknown
- 2011-05-31 IL IL213273A patent/IL213273A0/en active IP Right Grant
- 2011-06-01 CL CL2011001296A patent/CL2011001296A1/es unknown
- 2011-06-10 MA MA33933A patent/MA32892B1/fr unknown
- 2011-06-13 CR CR20110324A patent/CR20110324A/es unknown
- 2011-06-13 EC EC2011011127A patent/ECSP11011127A/es unknown
- 2011-06-14 CO CO11073992A patent/CO6382139A2/es active IP Right Grant
- 2011-07-13 ZA ZA2011/05164A patent/ZA201105164B/en unknown
2012
- 2012-09-14 US US13/619,920 patent/US8765128B2/en active Active
- 2012-09-14 US US13/619,730 patent/US8747850B2/en active Active
- 2012-09-14 US US13/619,910 patent/US8729249B2/en active Active
2014
- 2014-01-24 CL CL2014000181A patent/CL2014000181A1/es unknown
- 2014-03-13 IL IL231525A patent/IL231525B/en active IP Right Grant
2015
- 2015-07-03 PH PH12015501515A patent/PH12015501515A1/en unknown
- 2015-12-15 JP JP2015244007A patent/JP6074018B2/ja active Active
2016
- 2016-02-04 AU AU2016200725A patent/AU2016200725C1/en active Active
2017
- 2017-01-05 JP JP2017000641A patent/JP6309657B2/ja active Active
- 2017-06-09 AU AU2017203929A patent/AU2017203929B2/en active Active
- 2017-07-03 CY CY20171100707T patent/CY1119172T1/el unknown
2018
- 2018-11-09 CY CY181101191T patent/CY1121025T1/el unknown
- 2018-11-09 HR HRP20181868TT patent/HRP20181868T1/hr unknown

Also Published As

Publication number	Publication date
RU2011124751A (ru)	2013-01-10
BR122019023930B1 (pt)	2021-05-04
TWI459964B (zh)	2014-11-11
CN102227446A (zh)	2011-10-26
RU2560257C2 (ru)	2015-08-20
US20130109844A1 (en)	2013-05-02
DK2370468T3 (en)	2017-06-19
US8765128B2 (en)	2014-07-01
AU2016200725C1 (en)	2017-10-19
AU2017203929A1 (en)	2017-07-06
CN102227446B (zh)	2015-10-21
RS56204B1 (sr)	2017-11-30
JP5863458B2 (ja)	2016-02-16
PT3135691T (pt)	2018-11-27
MY185200A (en)	2021-04-30
KR20110097839A (ko)	2011-08-31
CA2743433A1 (en)	2010-06-24
AR074439A1 (es)	2011-01-19
JP6074018B2 (ja)	2017-02-01
IL231525A0 (en)	2014-04-30
CY1121025T1 (el)	2019-12-11
PH12015501515A1 (en)	2015-12-14
HK1162536A1 (zh)	2012-08-31
EP3431502A1 (en)	2019-01-23
PL3431502T3 (pl)	2020-12-28
RS58018B1 (sr)	2019-02-28
KR101838299B1 (ko)	2018-03-14
AU2009328318C1 (en)	2017-11-02
PT3431502T (pt)	2020-10-29
MX2011005677A (es)	2011-06-30
AU2009328318B2 (en)	2015-11-05
SA109300720B1 (ar)	2013-05-25
EP3135691A1 (en)	2017-03-01
US8729249B2 (en)	2014-05-20
SI2370468T1 (sl)	2017-08-31
CN103351438B (zh)	2016-04-20
US20110239316A1 (en)	2011-09-29
HK1190414A1 (zh)	2014-07-04
WO2010069765A1 (en)	2010-06-24
ES2697098T3 (es)	2019-01-22
MY192567A (en)	2022-08-29
HUE051288T2 (hu)	2021-03-01
BRPI0923231A2 (pt)	2016-01-26
EP3757132A1 (en)	2020-12-30
GEP20146207B (en)	2014-12-10
TW201023892A (en)	2010-07-01
CO6382139A2 (es)	2012-02-15
SA112331005B1 (ar)	2015-09-13
TWI523866B (zh)	2016-03-01
HRP20171011T8 (hr)	2019-01-25
IL213273A0 (en)	2011-07-31
ES2629855T3 (es)	2017-08-16
NZ593853A (en)	2013-03-28
US20130109841A1 (en)	2013-05-02
HRP20181868T1 (hr)	2019-01-11
JP2017099392A (ja)	2017-06-08
TW201446805A (zh)	2014-12-16
JP2012510280A (ja)	2012-05-10
PE20120343A1 (es)	2012-04-16
US8741290B2 (en)	2014-06-03
ZA201105164B (en)	2012-03-28
US20130109840A1 (en)	2013-05-02
SI3431502T1 (sl)	2021-01-29
SG171851A1 (en)	2011-07-28
HUE035047T2 (en)	2018-05-02
SG187518A1 (en)	2013-02-28
IL231525B (en)	2019-07-31
EP2370468A1 (en)	2011-10-05
EP3135691B1 (en)	2018-08-15
AU2016200725A1 (en)	2016-02-25
PT2370468T (pt)	2017-07-13
AU2009328318A1 (en)	2011-07-28
ES2827277T3 (es)	2021-05-20
BRPI0923231B1 (pt)	2020-04-28
MA32892B1 (fr)	2011-12-01
TN2011000216A1 (en)	2012-12-17
CL2011001296A1 (es)	2011-08-26
BRPI0923231B8 (pt)	2021-05-25
PL2370468T3 (pl)	2017-09-29
US8747850B2 (en)	2014-06-10
EP3431502B1 (en)	2020-07-22
GEP20135930B (en)	2013-10-10
ECSP11011127A (es)	2011-07-29
EP2370468B1 (en)	2017-04-05
SI3135691T1 (sl)	2018-12-31
JP2016117721A (ja)	2016-06-30
MX341014B (es)	2016-08-03
LT3135691T (lt)	2018-11-12
CY1119172T1 (el)	2018-02-14
CR20110324A (es)	2011-07-28
PL3135691T3 (pl)	2019-02-28
CN103351438A (zh)	2013-10-16
AU2016200725B2 (en)	2017-05-25
DK3135691T3 (en)	2018-11-19
JP6309657B2 (ja)	2018-04-11
AU2017203929B2 (en)	2019-03-28
RU2015127471A (ru)	2018-12-21
LT2370468T (lt)	2017-07-10
HUE040553T2 (hu)	2019-03-28
CA2743433C (en)	2019-06-11
HRP20171011T1 (hr)	2017-09-22

Publication	Publication Date	Title
CL2014000181A1 (es)	2014-07-25	Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11).
CL2015001356A1 (es)	2015-11-06	Anticuerpos bioespecificos egfr/c-met
CL2015001353A1 (es)	2015-10-02	Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
CL2007002835A1 (es)	2008-05-30	Anticuerpo monoclonal especifico para el receptor cxcr4; acido nucleico que lo codifica; vector y celula que lo comprenden; metodo de produccion; inmunoconjugado y composicion que lo comprende; y su uso para tratar cancer, trastornos inflamatorios y
CL2016002116A1 (es)	2017-05-12	Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13).
CL2015003090A1 (es)	2016-07-22	Proteínas de unión específicas y sus usos.
CL2011001382A1 (es)	2012-02-03	Anticuerpo o fragmento de union a antigeno especifico para el ligando 1 de muerte programada (pd-li); acido nucleico que lo codifica; vector; celula huesped; proceso de produccion; composicion que lo comprende; y su uso para tratar un trastorno disfuncional de celulas t.
CL2008002015A1 (es)	2008-11-21	Anticuerpo anti-receptor del factor de creciemiento de hepatocito (hgf)/receptor c-met; hibridoma que lo produce; acido nucleico que lo codifica; vector y celula huesped que los comprende; procedimiento de produccion; composicion que los comprende; su uso para tratar cancer; y metodo de diagnostico in vitro
CL2013000930A1 (es)	2014-03-28	Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
CL2015000094A1 (es)	2015-06-19	Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
CL2011000730A1 (es)	2012-02-03	Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer.
CL2015002526A1 (es)	2016-06-10	Anticuerpos anti-ox40 y métodos de uso de los mismos.(divisional de 545-13).
CL2011002784A1 (es)	2012-08-31	Anticuerpo anti-egfl7; acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion que lo comprende, y su uso para tratar un tumor, cancer o un trastorno proliferativo.
MX2014005728A (es)	2014-05-30	Anticuerpos especificos para antigeno de la superficie celular de trofoblasto-2 y sus usos.
CL2009000379A1 (es)	2012-02-24	Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
CL2014003465A1 (es)	2015-02-27	Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
BR112016027585A2 (pt)	2018-01-30	construções de anticorpo multiespecíficas
CL2011002417A1 (es)	2012-03-30	Anticuerpo especifico para fcrh5, receptor de superficie celular con homologia con las familias del receptor fc; anticuerpo anti-fcrh5 humanizado; polinucleotido que lo codifica; vector; celular huesped; metodo de obtencion; inmunoconjugado; composicion farmaceutica; y su uso para tratar cancer.
CL2017002244A1 (es)	2018-04-13	Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
CL2013002044A1 (es)	2014-05-09	Anticuerpo que une il-17a humano e il-17f humano; secuencia de adn que lo codifica; vector; celula huesped; proceso de produccion; composicion farmaceutica que lo comprende; y su uso para el tratamiento profilaxis de un trastorno patologico mediado por il-17a y/o il-17f.
CL2013003296A1 (es)	2014-07-25	Uso de un agonista del receptor 1 del factor de crecimiento anti-fibroblastos (fgfr1) para tratar enfermedades tales como sindrome de ovario poliquístico (pcos), sindrome metabólico, obesidad, estrato hepatitis no alcohólica (nash), entre otras; anticuerpo que se une con fgfr1; acido nucleico aislado; célula huesped.
CL2011002039A1 (es)	2012-03-30	Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19.
CL2011000769A1 (es)	2011-09-16	Anticuerpo biespecifico que se une especificamente al factor de crecimiento endotelial vascular humano (vegf) y a la angiopoyetina-2 humana (ang-2); acido nucleico que lo codifica; vector de expresion recombinante; celula hospedadora; metodo de produccion del anticuerpo; composicion farmaceutica que lo comprende; y su uso para tratar el cancer.
CL2013001290A1 (es)	2013-11-15	Anticuerpo aislado, o su fragmento, que se une a beta secretasa (bace1); acido nucleico que codifica el anticuerpo; celula huesped que comprende el acido nucleico; metodo para producir un anticuerpo; inmunoconjugado que comprende el anticuerpo; formulacion farmaceutica; uso del anticuerpo para tratar enfermedad o trastorno neurológico.
CL2011002304A1 (es)	2012-04-09	Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer.